Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

A federal court granted summary judgment to Edwards Lifesciences LLC on a Title VII failure to accommodate religious observance claim of a senior cardiovascular specialist who alleged that Edwards ...

This was the stock's second consecutive day of losses.

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Valeo Financial Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 28% in three years, versus a market return of ...

But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...